




RealRate

PHARMACEUTICAL 2022

Verrica Pharmaceuticals Inc.
Rank 285 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Verrica Pharmaceuticals Inc.
Rank 285 of 475



The relative strengths and weaknesses of Verrica Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verrica Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Verrica Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -167%, being 109% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	74,328
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,055
Liabilities, Non-Current	1,449
Other Assets	1,903
Other Compr. Net Income	-30
Other Expenses	0
Other Liabilities	16
Other Net Income	-4,172
Property and Equipment	3,894
Research and Development	15,929
Revenues	12,000
Selling, General and Administrative Expense	26,979

Output Variable	Value in 1000 USD
Assets	80,125
Liabilities	47,520
Expenses	42,908
Stockholders Equity	32,605
Net Income	-35,080
Comprehensive Net Income	-35,095
Economic Capital Ratio	-167%

